NRX Pharmaceuticals Inc

NASDAQ:NRXPUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

NRX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the development of therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The Company’s program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brains N-methyl-D-aspartate (NMDA) receptor and is being investigated in a Phase III trial under the United States Food and Drug Administrations (FDA) Special Protocol Agreement and Therapy Designation in patients with bipolar depression and suicidal ideation. The Company has also initiated a Phase IIb clinical trial in patients with Sub-Acute Suicidality, a substantially broader indication. Its product, NRX-100, is racemic ketamine, which is a generic anesthetic. It is engaged in the development of aviptadil acetate (ZYESAMI) for the treatment of respiratory failure in COVID-19.

Contact Information

Headquarters

1201 ORANGE STREET, SUITE 600WILMINGTON, DE, United States 19801

Phone

484-254-6134

Fax

302-575-1642

Executives

Interim Chief Executive Officer

Robert Besthof

Chief Financial Officer

Seth Van Voorhees

Chief Scientist, Director

Jonathan Javitt

Chief Corporate Officer, General Counsel, Secretary

Alessandra Daigneault

Chief Business Officer

Randy Guggenheimer